Wedbush Issues Negative Estimate for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Wedbush reduced their Q3 2025 EPS estimates for shares of Ultragenyx Pharmaceutical in a report issued on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($1.38) per share for the quarter, down from their prior estimate of ($1.36). Wedbush has a “Neutral” rating and a $34.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($5.58) EPS, Q2 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.43) EPS, FY2027 earnings at ($3.29) EPS and FY2028 earnings at $0.05 EPS.

A number of other equities analysts have also recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Wells Fargo & Company decreased their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, July 10th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Canaccord Genuity Group decreased their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Guggenheim restated a “buy” rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Stock Up 5.5%

NASDAQ RARE opened at $33.43 on Thursday. The stock has a market cap of $3.22 billion, a PE ratio of -6.05 and a beta of 0.21. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $57.99. The business has a 50 day moving average price of $29.98 and a two-hundred day moving average price of $32.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company’s revenue was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. lifted its stake in Ultragenyx Pharmaceutical by 4.5% during the third quarter. Vontobel Holding Ltd. now owns 10,935 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 471 shares during the last quarter. Wedge Capital Management L L P NC lifted its stake in Ultragenyx Pharmaceutical by 20.6% during the third quarter. Wedge Capital Management L L P NC now owns 43,179 shares of the biopharmaceutical company’s stock worth $1,299,000 after purchasing an additional 7,374 shares during the last quarter. Woodstock Corp lifted its stake in Ultragenyx Pharmaceutical by 36.3% during the third quarter. Woodstock Corp now owns 18,114 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 4,827 shares during the last quarter. Praxis Investment Management Inc. bought a new position in Ultragenyx Pharmaceutical during the third quarter worth $224,000. Finally, Osaic Holdings Inc. lifted its stake in Ultragenyx Pharmaceutical by 4,371.7% during the second quarter. Osaic Holdings Inc. now owns 4,740 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 4,634 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,456 shares of company stock valued at $328,486. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.